BRIEF published on 05/21/2024 at 12:12, 2 years 3 months ago Number of Guerbet shares and voting rights as of April 30, 2024 Share Capital Voting Rights Actions Transparency Guerbet
PRESS RELEASE published on 05/21/2024 at 12:07, 2 years 3 months ago GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 30 avril 2024 Déclaration relative au nombre de droits de vote et d'actions composant le capital de la société conformément à la réglementation en vigueur Déclaration Droits De Vote Capital Social Actions Réglementation
BRIEF published on 03/20/2024 at 18:05, 2 years 5 months ago Changements Importants au Conseil d'Administration de Guerbet Conseil D'administration Guerbet Imagerie Médicale Hugues Lecat Pharmaceutique
BRIEF published on 03/20/2024 at 18:05, 2 years 5 months ago Important Changes to the Guerbet Board of Directors Board Of Directors Pharmaceutical Guerbet Medical Imaging Hugues Lecat
PRESS RELEASE published on 03/20/2024 at 18:00, 2 years 5 months ago Guerbet: Evolution du Conseil d’Administration de Guerbet. Annonce de l'évolution du Conseil d'Administration de Guerbet avec la nomination de Hugues Lecat en qualité de censeur et futur Président, et déclarations des principaux intéressés Assemblée Générale Conseil D'administration Guerbet Imagerie Médicale Hugues Lecat
PRESS RELEASE published on 03/20/2024 at 18:00, 2 years 5 months ago Guerbet: Change in Guerbet’s Board of Directors. Guerbet appoints Hugues Lecat as a non-voting director with plans for him to become Chairman, enhancing the company's governance and strategic vision for future success Board Of Directors Guerbet Medical Imaging Chairman Appointment Hugues Lecat
BRIEF published on 03/20/2024 at 17:50, 2 years 5 months ago Guerbet Announces Solid Growth and Improved Profitability in 2023 Full-Year Results Financial Results Profitability Guerbet Healthcare Imaging 2023 Growth
BRIEF published on 03/20/2024 at 17:50, 2 years 5 months ago Guerbet annonce une croissance solide et une rentabilité améliorée pour ses résultats annuels 2023 Résultats Financiers Rentabilité Guerbet Imagerie Médicale Croissance 2023
PRESS RELEASE published on 03/20/2024 at 17:45, 2 years 5 months ago Guerbet: 2023 full-year results. Guerbet publishes solid 2023 full-year results with revenue growth of 5.9% at CER and EBITDA margin exceeding target. Confirms outlook for 2024 with revenue growth > 8% and higher profitability Revenue Growth 2024 Outlook EBITDA Margin Guerbet 2023 Full-year Results
PRESS RELEASE published on 03/20/2024 at 17:45, 2 years 5 months ago Guerbet: Résultats annuels 2023. Publication des résultats annuels 2023 de Guerbet avec une croissance solide de l’activité et une rentabilité supérieure aux objectifs. Perspectives 2024 confirmées avec prévisions de croissance et rentabilité en hausse Croissance Perspectives 2024 Guerbet Résultats Annuels Rentabilité
Published on 09/11/2026 at 15:25, 1 hour 11 minutes ago Revolve Signs Agreement to Acquire 9.6 MW Operating Wind Project in the US and Secures Project-Level Debt Financing with EDC and Vancity
Published on 09/11/2026 at 15:00, 1 hour 36 minutes ago Regentis Biomaterials Reports First Half 2026 Financial Results and Provides Corporate Update
Published on 09/11/2026 at 14:30, 2 hours 6 minutes ago AIAI Holdings Enters into Extended Lock-up Agreements to Protect Long-Term Stockholder Value
Published on 09/11/2026 at 13:58, 2 hours 38 minutes ago BlackBerry Radar Advances Asset Intelligence for Transportation
Published on 09/11/2026 at 13:00, 3 hours 36 minutes ago Silver Tiger Intersects 2.1 Metres of 7.72 Kilograms Per Tonne Silver Equivalent in the Caleigh Vein Including 0.53 Metres of 29.62 Kilograms
Published on 09/11/2026 at 16:00, 36 minutes ago Deutsche Postbank Funding Trust III published semi-annual report
Published on 09/11/2026 at 16:00, 36 minutes ago Form 8.3 - IPConcept (Luxemburg) S.A.: SONNTAG Premium
Published on 09/11/2026 at 15:29, 1 hour 7 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/11/2026 at 15:24, 1 hour 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: Segro PLC
Published on 09/11/2026 at 15:22, 1 hour 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Schroders PLC
Published on 09/11/2026 at 07:00, 9 hours 36 minutes ago Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 9 hours 36 minutes ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 9 hours 36 minutes ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 21 hours 6 minutes ago Availability of the 2026 Interim Financial Report
